GSK Pharma’s Q4 net profit at Rs.106 cr

GSK’s board has suggested a dividend of 500% on equity share capital

The Dollar Business Bureau

GlaxoSmithKline, a British pharma company, on Wednesday, reported Rs.105.98 crore of standalone net profit for Q4 ended March 2016.

The London-based company’s net profit for the corresponding period in FY15 stood at Rs.102.85 crore. Founded in 2000 with the merging of Glaxo Wellcome and SmithKline Beecham, it became the 6th largest pharma company in the world.

In a filing to BSE, GlaxoSmithKline revealed that the revenue generated from operations of the company for the considered quarter stood at Rs.692.97 cr, which was an increase from Rs.618.06 crore of income generated for the reviewed period in FY15.

The net profit of GSK in FY16 was Rs.375 cr, while it was Rs.471.65 crore for FY15.

The standalone income was calculated at Rs.2,756.96 cr for FY16 while the same for FY15 was Rs.3,287.58 crore.

The accounting year of GS has been changed from January-December to April-March. The change came into effect from the last fiscal. Hence, the given financial statements for FY15 are for 15 months i.e; January 2015 to March 2015.

Keeping the changed fiscal year in mind, the current year’s data cannot be compared with the previous one, GSK said in a statement.

GSK, in another filing, stated that the board has suggested for a dividend of 500% on equity share capital, which is Rs.50 per equity share for FY16.

The shares of GSK closed at Rs.3,425.30 on BSE, which is a slight increase of 0.97% from its previous close.

Related Topics:
The Dollar Business Bureau - May 26, 2016 12:00 IST